galidesivir and Rift-Valley-Fever

galidesivir has been researched along with Rift-Valley-Fever* in 1 studies

Other Studies

1 other study(ies) available for galidesivir and Rift-Valley-Fever

Article	Year
Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters. Antiviral research, 2018, Volume: 156 Rift Valley fever virus (RVFV) is a mosquito-borne pathogen endemic to sub-Saharan Africa and the Arabian Peninsula. There are no approved antiviral therapies or vaccines available to treat or prevent severe disease associated with RVFV infection in humans. The adenosine analog, galidesivir (BCX4430), is a broad-spectrum antiviral drug candidate with in vitro antiviral potency (EC Topics: Adenine; Adenosine; Animals; Antiviral Agents; Disease Models, Animal; Injections, Intramuscular; Injections, Intraperitoneal; Liver; Mesocricetus; Purine Nucleosides; Pyrrolidines; Rift Valley Fever; Rift Valley fever virus; Spleen; Survival Analysis; Treatment Outcome	2018

Article

Year

Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters.

Antiviral research, 2018, Volume: 156

Rift Valley fever virus (RVFV) is a mosquito-borne pathogen endemic to sub-Saharan Africa and the Arabian Peninsula. There are no approved antiviral therapies or vaccines available to treat or prevent severe disease associated with RVFV infection in humans. The adenosine analog, galidesivir (BCX4430), is a broad-spectrum antiviral drug candidate with in vitro antiviral potency (EC

Topics: Adenine; Adenosine; Animals; Antiviral Agents; Disease Models, Animal; Injections, Intramuscular; Injections, Intraperitoneal; Liver; Mesocricetus; Purine Nucleosides; Pyrrolidines; Rift Valley Fever; Rift Valley fever virus; Spleen; Survival Analysis; Treatment Outcome

2018